Unaudited Financial Statements (Consolidated & Standalone) for the first quarter ended 30th June 2026 alongwith Limited Review report by Auditors

UNICHEMI LABORATORIES LTD. ..........,;;;;=-......, 11th August 2026 Department of Corporate Services National Stock Exchange of India, BSE Limited, Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Mumbai – 400 001 Bandra (East), Mumbai – 400 051 Script Code: 506690 Symbol: UNICHEMLAB Dear Sir/Madam, Sub: Outcome of Board Meeting We would like to inform you that the Board of Directors at its Meeting held today, i.e. Tuesday, 11th August 2026 approved the Unaudited Financial Statements (Consolidated & Standalone) for the first quarter ended 30th June 2026. Enclosed herewith are the Unaudited Financial Statements (Consolidated & Standalone) for the first quarter ended 30th June 2026 alongwith Limited Review report by Auditors. The Board meeting commenced at 12:00 noon and concluded at 1:45 p.m. The same will also be made available on the Company’s website www.unichemlabs.com as well as on www.bseindia.com and www.nseindia.com. Kindly take the same on your records. Thanking you, FOR UNICHEM LABORATORIES LIMITED PRADEEP BHANDARI Head – Legal & Company Secretary Encl.: a/a Registered Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400 067 Maharashtra, India. Tel.:+91 (22) 66474100 · Website:www.unichemlabs.com · CIN: L99999MH1962PLC012451 UNICHEM LABORATORIES LIMITED Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West}, Mumbai 400 067, Maharashtra, India. Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451 Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June 2026 f Crores Quarter ended Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Particulars Unaudited Unaudited Unaudited Audited I Revenue from operations 632.62 575.12 526.60 2,201.85 II Other income 15.61 23.47 6.82 63.06 Ill Total income (1+11) 648.23 598.59 533.42 2,264.91 IV EXPENSES Cost of materials consumed 190.02 184.03 217.48 768.83 Purchase of stock-in-trade 67.25 91.81 51.01 231.51 Changes in inventories of stock-in-trade, finished goods and work-in- 31.32 (7.82) (23.44) 20.21 progress Employee benefits expense (Refer note 6) 103.31 92.85 107.42 396.63 Finance costs 6.62 9.39 6.54 31.59 Depreciation and amortization expenses 29.94 30.61 31.79 125.12 Other expenses 170.78 166.57 151.64 600.50 Total expenses (IV) 599.24 567.44 542.44 2,174.39 V Share of profit/ (loss) in associate (net of tax) - - - - VI Profit/ (Loss) before exceptional items and tax (111-IV+V) 48.99 31.15 (9.02) 90.52 VII Exceptional items -expenses/(income) (Refer note 5) - 12.36 - (201.86) VIII Profit/ (Loss) before tax (VI-VII) 48.99 18.79 (9.02) 292.38 IX Tax expense (Refer note 4) (1) Current tax 0.72 2.96 0.96 3.57 (2) Deferred tax charge/ (credit) 6.80 4.92 0.05 35.53 (3) Short/ (excess) provision for tax (earlier years) - - 0.44 0.44 7.52 7.88 1.45 39.54 X Profit/ (Loss) for the period after tax (VIII-IX) 41.47 10.91 (10.47) 252.84 XI Other Comprehensive Income I (Loss) A. (i) Items that will not be reclassified subsequently to profit or loss -Remeasurement of the net defined benefit plan 0.28 3.53 4.87 10.15 (ii) Income tax (expense) / credit relating to items that will not be reclassified to profit or loss -Remeasurement of the net defined benefit plan (0.07) (0.88) - (2.55) B. (i) Items that will be reclassified to profit or loss (Foreign currency translation difference\ -Foreign currency translation difference (3.27) 6.51 (1.82) 4.39 (ii) Income tax relating to items that will be reclassified to profit or loss -Foreign currency translation difference - - - - Total of Other Comprehensive Income I (Loss) (3.06) 9.16 3.05 11.99 XII Total Comprehensive lncome/(loss) for the period (X+XI) 38.41 20.07 (7.42) 264.83 XIII Paid-up equity share capital (Face value off 2/-per share) 14.08 14.08 14.08 14.08 XIV Other Equity (Reserves excluding revaluation reserve) 2,688.66 xv Earnings per equity share (Face value off 2/-per share) (not annualized) (1) Basic 5.89 1.55 (1.49) 35.91 (2) Diluted 5.89 1.55 (1.49) 35.85 UNICHEM UNICHEM LABORATORIES LIMITED Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India. Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451 Notes: 1 The above unaudited consolidated financial results ("the Statement") for the quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th August, 2026. The statutory auditors have expressed an unmodified conclusion on these consolidated financial results for the quarter ended 30th June, 2026. 2 The above Statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. 3 Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'. 4 In respect of the Company, there is no current tax charge for the period, considering set-off of unabsorbed tax depreciation, capital loss and business loss. Further, deferred tax liability (net) has been recorded. In respect of subsidiaries, income tax is recognised as per applicable tax laws. 5 Exceptional Items comprise of the following: ii!' Crores Quarter ended Year ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Employee benefit expense (refer note 6 below) - 12.36 - 15.40 Net (gain)/ loss on disposal of land & building (erstwhile Registered office] - - - (275.52) Interest on European commission fine (refer note 7 below) - - - 58.26 Total Exceptional Items - expenses/ (income) . 12.36 . (201.86) 6 The New Labour Codes had resulted in a one-time increase in provision for employee benefits on account of recognition of past service costs of ii!' 15.40 crores which is disclosed as Exceptional Items during the year ended 31st March, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes. 7 The Company and its subsidiary Niche Generics Ltd. ("Niche") had received a demand order dated 17th September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same was fully settled by the Company on 28th October 2025 after adjusting the payments of Euro 2.79 million already made by Niche in instalments to EU. In regard to above, the Company had fully recognised a provision in books towards payment of fine amounting to Euro 13.96 million towards EU fine during year ended 31st March 2024 and the balance amount representing the interest was recorded in year ended 31st March 2026 under exceptional items. 8 The figures for the quarter ended 31st March, 2026 are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the quarter ended 31st December, 2025 which were subjected to a limited review. By Order of the Board SIGNED FOR IDENTIFICATION For Unichem Laboratories Limited BHAVIN Digitally signed by BHAVIN Pabitrakumar ';_);'DOR<'/,,._ S KU AR PE AN DD IAR A +S DU 0a 5R te 'E 3:N 2 00 'D 2R 6A . 0K 8A .1P 1A 1D 3I :A 2 7:18 Kalipada D 13a :t 0e 0: :2 10 82 +6 0.0 58 '. 31 ~ '. ~ICM 4U 00M 0B 67A ,..I _-~ N. A. SHAH ASSOCIATES LLP Bhattacharyya 1i/l•·a'I, MUMBAI Pabitrakumar Kalipada Bhattacharyya Place: Mumbai Managing Director and Chief Executive Officer Date: 11th Auaust, 2026 DIN: 07131152 UNICHEM N. A. SHAH ASSOCIATES LLP Chartered Accountants Independent Auditor's Review Report on Quarterly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors Unichem Laboratories Limited 1. We have reviewed the accompanying statement of consolidated unaudited financial results of Unichem Laboratories Limited ("the Holding Company"), comprising its subsidi [Showing first 8,000 characters — download PDF for full document]